{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-230786","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.978574+00:00","generated_at":"2026-06-10T22:21:09.667772+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"AN2 Therapeutics appoints CFO Lucy Day as Principal Accounting Officer; VP Controller departs","bullets":["Lucy Day, current CFO, adds role of Principal Accounting Officer effective September 1, 2023.","Michael Nazak, Vice President & Corporate Controller, to depart on September 15, 2023.","Annie Yoshiyama hired as new Vice President, Finance and Corporate Controller."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-230786","json":"https://secwatch.observer/filing/0001193125-23-230786.json","markdown":"https://secwatch.observer/filing/0001193125-23-230786.md","text":"https://secwatch.observer/filing/0001193125-23-230786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/d514862d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:21:09.667772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0de8b045f3","claim":"Lucy Day was appointed as Principal Accounting Officer at AN2 Therapeutics, Inc..","evidence_excerpt":"On September 1, 2023, the Company’s Board of Directors appointed Lucy Day, the Company’s current Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer effective as of September 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"3e7896d42f","claim":"Annie Yoshiyama was appointed as Vice President, Finance and Corporate Controller at AN2 Therapeutics, Inc..","evidence_excerpt":"The Company has hired Annie Yoshiyama, previously Senior Vice President, Finance and Chief Accounting Officer at Tricida, Inc., as its new Vice President, Finance and Corporate Controller.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"hired"},{"label":"Role","value":"Vice President, Finance and Corporate Controller"}],"fact_type":"executive_change"},{"claim_id":"fc51acad82","claim":"Michael Nazak departed as Vice President, Corporate Controller at AN2 Therapeutics, Inc..","evidence_excerpt":"Michael Nazak, Vice President, Corporate Controller and the prior Principal Accounting Officer, will depart the Company effective September 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523230786/0001193125-23-230786-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will depart"},{"label":"Role","value":"Vice President, Corporate Controller"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}